GlassScriptPhysician profile
Concepcion Neil
NPI 1710363759
$4,500.51
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,824 · 2022: $891 · 2023: $691 · 2024: $93.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Consulting Fee: $18.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.28 |
| Consulting Fee | $18.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,200.00 | 2021 | |
| Biotronik INC. | $979.02 | 2021-2023 | Biomonitor |
| Amgen INC. | $285.15 | 2021-2023 | Repatha |
| Impulse Dynamics (USA) INC. | $223.68 | 2022-2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.25 | 2021-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $161.52 | 2021-2023 | |
| Medtronic, INC. | $157.73 | 2021 | |
| Abbott Laboratories | $139.10 | 2021 | |
| Cvrx, INC. | $123.59 | 2023-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $109.65 | 2021-2022 | |
| Esperion Therapeutics, INC. | $102.76 | 2021-2023 | Nexletol |
| Boston Scientific Corporation | $77.28 | 2021-2024 | Varithena Administration Pack |
| Arbor Pharmaceuticals, INC. | $74.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.49 | 2022-2023 | Kerendia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $68.08 | 2021-2023 | Eliquis |
| Amarin Pharma, INC. | $42.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $37.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.41 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $30.90 | 2022-2023 | Verquvo |
| Bard Peripheral Vascular, INC. | $30.82 | 2022 | |
| Pfizer INC. | $26.23 | 2022 | |
| Kerecis Limited | $23.34 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| W. L. Gore & Associates, INC. | $19.71 | 2023 | Gore Cardioform Septal Occluder |
| Baxter Healthcare | $18.45 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $17.94 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.58 | 2021 | |
| Inari Medical, INC. | $14.68 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lundbeck LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Concepcion Neil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.